GLOBEALERT
Business● LowSep 23 · Sep 23, 2026, 2:00 AM

Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts

GlobeAlert Desk · curated from South China Morning Post · global

China’s edge in fast, cost-effective early clinical trials has propelled its emergence as a global biopharmaceutical powerhouse, but there is a risk that the United States could take steps to curb that advantage, according to analysts. US lawmakers and officials at the Food and Drug Administration (FDA) have raised the alarm about American pharmaceutical companies’ growing reliance on conducting early clinical trials in China, flagging the opaqueness of the process and the need to keep medical...

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.

GlobeAlert context

What the desk knows about this story

Threat level
1 Low

Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.

Sources
1 publisher

Single-source so far. Treat details as unconfirmed until more publishers report.

Category
Business

Not flagged as developing.

More in Business

Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts · GlobeAlert